Detalhe da pesquisa
1.
XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Breast Cancer Res
; 25(1): 67, 2023 06 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37308971
2.
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer.
Breast Cancer Res
; 23(1): 8, 2021 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33451345
3.
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial.
Breast Cancer Res
; 22(1): 124, 2020 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-33176887
4.
Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer.
Eur J Cancer Care (Engl)
; 28(6): e13164, 2019 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-31571304
5.
Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial.
Lancet Oncol
; 19(7): 987-998, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29880292
6.
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial.
Lancet Oncol
; 18(4): 545-554, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-28238593
7.
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer.
Breast Cancer Res Treat
; 165(3): 601-609, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28681171
8.
A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.
Breast Cancer Res Treat
; 163(3): 535-544, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28324268
9.
Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol
; 17(6): 811-821, 2016 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-27155741
10.
SOLTI NeoPARP: a phase II randomized study of two schedules of iniparib plus paclitaxel versus paclitaxel alone as neoadjuvant therapy in patients with triple-negative breast cancer.
Breast Cancer Res Treat
; 154(2): 351-7, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26536871
11.
Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
BMC Med
; 17(1): 8, 2019 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30621698
12.
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study.
Breast
; 74: 103681, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38377732
13.
Applications of CRISPR Technology to Breast Cancer and Triple Negative Breast Cancer Research.
Cancers (Basel)
; 15(17)2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37686639
14.
Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?
Cancers (Basel)
; 14(5)2022 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-35267409
15.
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.
Eur J Cancer
; 168: 12-24, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35429901
16.
Her2-Positive Cancers and Antibody-Based Treatment: State of the Art and Future Developments.
Cancers (Basel)
; 13(22)2021 Nov 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-34830927
17.
Phase I/II study to assess the clinical pharmacology and safety of single ascending and multiple subcutaneous doses of PF-06881894 in women with non-distantly metastatic breast cancer.
Cancer Chemother Pharmacol
; 88(6): 1033-1048, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34618197
18.
Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial.
NPJ Breast Cancer
; 7(1): 145, 2021 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34824288
19.
Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study.
Front Oncol
; 11: 645026, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34307126
20.
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer.
Front Oncol
; 11: 827625, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-35223459